

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 16, 2025

Brilliant Violet 421(TM) anti-mouse CD279 (PD-1)

RRID:AB_2561447

Type: Antibody

Proper Citation

(BioLegend Cat# 135218, RRID:AB_2561447)

Antibody Information

URL: http://antibodyregistry.org/AB_2561447

Proper Citation: (BioLegend Cat# 135218, RRID:AB_2561447)

Target Antigen: CD279

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, SB

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: mouse

Clone ID: Clone 29F.1A12

Antibody ID: AB_2561447

Vendor: BioLegend

Catalog Number: 135218

Alternative Catalog Numbers: 135217, 135221

Record Creation Time: 20241016T232351+0000

Record Last Update: 20250118T060313+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD279 (PD-1).

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Borys SM, et al. (2024) NK cells restrain cytotoxic CD8+ T cells in the submandibular gland via PD-1-PD-L1. Science immunology, 9(102), eadl2967.

Wang X, et al. (2024) Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer cell, 42(10), 1729.

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis. Cell reports, 43(9), 114690.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med (New York, N.Y.), 5(10), 1237.

Voltarelli VA, et al. (2024) Moderate-intensity aerobic exercise training improves CD8+ tumor-infiltrating lymphocytes effector function by reducing mitochondrial loss. iScience, 27(6), 110121.

DuCote TJ, et al. (2024) EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. Cancer research communications, 4(2), 388.

Graziano V, et al. (2023) Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer, 11(8).

Ausejo-Mauleon I, et al. (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer cell, 41(11), 1911.

Liu Z, et al. (2023) Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer cell, 41(11), 1852.

Ma L, et al. (2023) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. *Cell*, 186(15), 3148.

Ramirez-Valdez RA, et al. (2023) Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. *Cell reports*, 42(6), 112599.

Li J, et al. (2023) Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. *Cancer cell*, 41(6), 1152.

Parmigiani E, et al. (2022) Interferon- γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. *Developmental cell*, 57(15), 1847.

Dähling S, et al. (2022) Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. *Immunity*, 55(4), 656.

Kitajima S, et al. (2022) MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. *Cancer cell*, 40(10), 1128.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. *Cell reports*, 41(3), 111478.

Miyai Y, et al. (2022) Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. *Life science alliance*, 5(6).

Synn CB, et al. (2022) SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. *Clinical & translational immunology*, 11(1), e1364.

Baharom F, et al. (2022) Systemic vaccination induces CD8⁺ T cells and remodels the tumor microenvironment. *Cell*, 185(23), 4317.

Delacher M, et al. (2021) Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. *Immunity*, 54(4), 702.